275 related articles for article (PubMed ID: 33631116)
1. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants.
Bressan RB; Southgate B; Ferguson KM; Blin C; Grant V; Alfazema N; Wills JC; Marques-Torrejon MA; Morrison GM; Ashmore J; Robertson F; Williams CAC; Bradley L; von Kriegsheim A; Anderson RA; Tomlinson SR; Pollard SM
Cell Stem Cell; 2021 May; 28(5):877-893.e9. PubMed ID: 33631116
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
[TBL] [Abstract][Full Text] [Related]
3. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
[TBL] [Abstract][Full Text] [Related]
4. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.
Brien GL; Bressan RB; Monger C; Gannon D; Lagan E; Doherty AM; Healy E; Neikes H; Fitzpatrick DJ; Deevy O; Grant V; Marqués-Torrejón MA; Alfazema N; Pollard SM; Bracken AP
Nat Genet; 2021 Aug; 53(8):1221-1232. PubMed ID: 34294917
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
7. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
[TBL] [Abstract][Full Text] [Related]
8. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
9. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
[TBL] [Abstract][Full Text] [Related]
10. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling.
Chen KY; Bush K; Klein RH; Cervantes V; Lewis N; Naqvi A; Carcaboso AM; Lechpammer M; Knoepfler PS
Commun Biol; 2020 Jul; 3(1):363. PubMed ID: 32647372
[TBL] [Abstract][Full Text] [Related]
12. Stem cell models help crack regional oncohistone codes driving childhood gliomas.
Klein RH; Knoepfler PS
Cell Stem Cell; 2021 May; 28(5):785-787. PubMed ID: 33961758
[TBL] [Abstract][Full Text] [Related]
13. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
[TBL] [Abstract][Full Text] [Related]
14. Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
Voon HPJ; Hii L; Garvie A; Udugama M; Krug B; Russo C; Chüeh AC; Daly RJ; Morey A; Bell TDM; Turner SJ; Rosenbluh J; Daniel P; Firestein R; Mann JR; Collas P; Jabado N; Wong LH
Genome Biol; 2023 Dec; 24(1):284. PubMed ID: 38066546
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma.
Funato K; Smith RC; Saito Y; Tabar V
Cell Stem Cell; 2021 May; 28(5):894-905.e7. PubMed ID: 33631117
[TBL] [Abstract][Full Text] [Related]
16. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
17. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
[TBL] [Abstract][Full Text] [Related]
18. H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas.
Garcia-Fabiani MB; Haase S; Banerjee K; McClellan B; Zhu Z; Mujeeb A; Li Y; Yu J; Kadiyala P; Taher A; Núñez FJ; Alghamri MS; Comba A; Mendez FM; Nicola Candia AJ; Salazar B; Koschmann C; Nunez FM; Edwards M; Qin T; Sartor MA; Lowenstein PR; Castro MG
bioRxiv; 2023 Jun; ():. PubMed ID: 37398299
[TBL] [Abstract][Full Text] [Related]
19. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
[TBL] [Abstract][Full Text] [Related]
20. Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.
Oliveira VF; De Sousa GR; Dos Santos AC; Saggioro FP; Machado HR; de Oliveira RS; Tone LG; Valera ET
Childs Nerv Syst; 2021 Feb; 37(2):375-382. PubMed ID: 32766947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
